Browse Catapults

Transforming UK medical imaging

Integrated regional imaging services into Medicines Discovery Catapult
Established UK PET Network with leading academic centres of excellence
Relaunched radiochemistry at the Wolfson Molecular Imaging Centre (WMIC)
National leadership of industry-academic PET platform

The Medicines Discovery Catapult is working to ensure the UK remains a world leader in Positron Emission Tomography (PET) Imaging, a data-rich non-invasive imaging modality that offers huge potential across the life sciences and is highly amenable to advances in AI.

In April 2019, The Catapult integrated in-vivo imaging services into its pre-clinical portfolio. It promoted and drove adoption of these advanced techniques through collaborative research programmes across a range of disease areas, accelerating drug R&D for UK SMEs.

The Catapult’s contribution of PET Imaging expertise and infrastructure has supported two of these UK SMEs in securing over £12.5 million of private investment, with another obtaining a $360 million licensing deal for one of their drug candidates.

In 2021 the Catapult created the UK PET Network with leading academic centres of excellence. The network has a clear seven-year plan to leverage UK innovation, expertise, and infrastructure to keep the UK at the leading edge of this important and valuable technology. This has led to the creation of a multimillion pound national PET transaction platform co-supported by industry and UK Research & Innovation (UKRI).

Adding to these PET Imaging capabilities, the Catapult relaunched radiochemistry at Manchester’s Wolfson Molecular Imaging Centre (WMIC) in August 2021. WMIC houses a multi-million-pound cyclotron that allows the Medicines Discovery Catapult to supply hard-to-make radiochemicals to drug discovery biotechs and academic innovators – increasing the UK’s potential to discover new and better therapies for patients faster.